Hepatic failure associated with immune checkpoint inhibitors: An analysis of the Food and Drug Administration Adverse Event Reporting System database

Hepatic failure induced by immune checkpoint inhibitors (ICIs) has been reported in only a few case series and case reports.

[1]  D. Davenport,et al.  Predictors of Liver Failure in Non-Cirrhotic Patients Undergoing Hepatectomy , 2022, World Journal of Surgery.

[2]  O. Shibolet,et al.  Acute Liver Failure following a Single Dose of Atezolizumab, as Assessed for Causality Using the Updated RUCAM , 2022, Case reports in gastrointestinal medicine.

[3]  N. Lennon,et al.  Durvalumab plus tremelimumab alone or in combination with low-dose or hypofractionated radiotherapy in metastatic non-small-cell lung cancer refractory to previous PD(L)-1 therapy: an open-label, multicentre, randomised, phase 2 trial. , 2022, The Lancet. Oncology.

[4]  Yuqing Zhu,et al.  The efficacy and safety of combined ipilimumab and nivolumab versus ipilimumab in patients with Stage III/IV unresectable melanoma: A systematic review and meta-analysis , 2021, Journal of Cancer Research and Therapeutics.

[5]  Layla Shojaie,et al.  Mechanisms of immune checkpoint inhibitor-mediated liver injury , 2021, Acta pharmaceutica Sinica. B.

[6]  Weijia Wang,et al.  Sex-related differences in the efficacy of immune checkpoint inhibitors in malignancy: a systematic review and meta-analysis , 2021, Aging.

[7]  C. Xie,et al.  Immune Checkpoint Inhibitor Associated Hepatotoxicity in Primary Liver Cancer Versus Other Cancers: A Systematic Review and Meta‐Analysis , 2021, Frontiers in Oncology.

[8]  Lindsey N Teal,et al.  Fulminant Hepatic Failure after Chemosaturation with Percutaneous Hepatic Perfusion and Nivolumab in a Patient with Metastatic Uveal Melanoma , 2021, Case reports in oncological medicine.

[9]  Chenyu Zhang,et al.  Immune-related adverse events associated with immune checkpoint inhibitors: An updated comprehensive disproportionality analysis of the FDA adverse event reporting system. , 2021, International immunopharmacology.

[10]  G. Mills,et al.  Association Between Sex and Immune-Related Adverse Events During Immune Checkpoint Inhibitor Therapy. , 2021, Journal of the National Cancer Institute.

[11]  A. Ido,et al.  [Pulse steroid therapy to treat liver injury with risk of liver failure due to immune-related adverse events:a case report]. , 2021, Nihon Shokakibyo Gakkai zasshi = The Japanese journal of gastro-enterology.

[12]  Siddharth Singh,et al.  Systematic review with meta‐analysis: safety and tolerability of immune checkpoint inhibitors in patients with pre‐existing inflammatory bowel diseases , 2020, Alimentary pharmacology & therapeutics.

[13]  J. Hart,et al.  Hepatotoxicity From Immune Checkpoint Inhibitors: A Systematic Review and Management Recommendation , 2020, Hepatology.

[14]  N. Chalasani,et al.  Clinical Characteristics and Adverse Impact of Hepatotoxicity due to Immune Checkpoint Inhibitors. , 2019, The American journal of gastroenterology.

[15]  B. Liu,et al.  Randomised efficacy and safety results for atezolizumab (Atezo) + bevacizumab (Bev) in patients (pts) with previously untreated, unresectable hepatocellular carcinoma (HCC) , 2019, Annals of Oncology.

[16]  G. Coukos,et al.  Adverse effects of immune-checkpoint inhibitors: epidemiology, management and surveillance , 2019, Nature Reviews Clinical Oncology.

[17]  U. Dafni,et al.  Immune checkpoint inhibitors, alone or in combination with chemotherapy, as first-line treatment for advanced non-small cell lung cancer. A systematic review and network meta-analysis. , 2019, Lung cancer.

[18]  I. Benhar,et al.  Immune checkpoint inhibitor combinations: Current efforts and important aspects for success. , 2019, Drug resistance updates : reviews and commentaries in antimicrobial and anticancer chemotherapy.

[19]  Failure.  Guideline for diagnosis and treatment of liver failure (2018 edition) , 2018 .

[20]  R. Sullivan,et al.  Fatal Toxic Effects Associated With Immune Checkpoint Inhibitors: A Systematic Review and Meta-analysis , 2018, JAMA oncology.

[21]  Ling-Long Tang,et al.  Comparative safety of immune checkpoint inhibitors in cancer: systematic review and network meta-analysis , 2018, British Medical Journal.

[22]  P. Keegan,et al.  FDA analyses of survival in older adults with metastatic non-small cell lung cancer in controlled trials of PD-1/PD-L1 blocking antibodies. , 2018, Seminars in oncology.

[23]  D. Samuel,et al.  Characterization of liver injury induced by cancer immunotherapy using immune checkpoint inhibitors. , 2018, Journal of hepatology.

[24]  Jianxing He,et al.  Risk of hepatotoxicity in cancer patients treated with immune checkpoint inhibitors: A systematic review and meta‐analysis of published data , 2017, International journal of cancer.

[25]  Xinghuan Wang,et al.  The impact of surgical treatments for lower urinary tract symptoms/benign prostatic hyperplasia on male erectile function , 2016, Medicine.

[26]  K. Reddy,et al.  Acetaminophen-related hepatotoxicity. , 2013, Clinics in liver disease.

[27]  矢野 崇.  Diagnosis and treatment of liver failure , 2009 .

[28]  D. Madigan,et al.  The role of data mining in pharmacovigilance , 2005, Expert opinion on drug safety.

[29]  M. Lindquist,et al.  A comparison of measures of disproportionality for signal detection in spontaneous reporting systems for adverse drug reactions , 2002, Pharmacoepidemiology and drug safety.